BookR: School of Health Core Facilities Booking
PubMed Publications| Keyword search (4,164 papers available) |  |
"Janssen I" Authored Publications:
| Title | Authors | PubMed ID | |
|---|---|---|---|
| 1 | Economic burden of insomnia symptoms in Canada | Chaput JP; Janssen I; Sampasa-Kanyinga H; Carney CE; Dang-Vu TT; Davidson JR; Robillard R; Morin CM; | 36319579 PERFORM |
| 2 | L’obésité chez l’adulte : ligne directrice de pratique clinique. | Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, Adamo K, Alberga A, Bell R, Boulé N, Boyling E, Brown J, Calam B, Clarke C, Crowshoe L, Divalentino D, Forhan M, Freedhoff Y, Gagner M, Glazer S, Grand C, Green M, Hahn M, Hawa R, Henderson R, Hong D, Hung P, Janssen I, Jacklin K, Johnson-Stoklossa C, Kemp A, Kirk S, Kuk J, Langlois MF, Lear S, McInnes A, Macklin D, Naji L, Manjoo P, Morin MP, Nerenberg K, Patton I, Pedersen S, Pereira L, Piccinini-Vallis H, Poddar M, Poirier P, Prud | 33288515 HKAP |
| 3 | Obesity in adults: a clinical practice guideline. | Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, Adamo K, Alberga A, Bell R, Boulé N, Boyling E, Brown J, Calam B, Clarke C, Crowshoe L, Divalentino D, Forhan M, Freedhoff Y, Gagner M, Glazer S, Grand C, Green M, Hahn M, Hawa R, Henderson R, Hong D, Hung P, Janssen I, Jacklin K, Johnson-Stoklossa C, Kemp A, Kirk S, Kuk J, Langlois MF, Lear S, McInnes A, Macklin D, Naji L, Manjoo P, Morin MP, Nerenberg K, Patton I, Pedersen S, Pereira L, Piccinini-Vallis H, Poddar M, Poirier P, Prud | 32753461 HKAP |
| Title: | Economic burden of insomnia symptoms in Canada | ||||
| Authors: | Chaput JP, Janssen I, Sampasa-Kanyinga H, Carney CE, Dang-Vu TT, Davidson JR, Robillard R, Morin CM | ||||
| Link: | https://pubmed.ncbi.nlm.nih.gov/36319579/ | ||||
| DOI: | 10.1016/j.sleh.2022.09.010 | ||||
| Publication: | Sleep health | ||||
| Keywords: | Economic cost; Health care cost; Insomnia; Public health; | ||||
| PMID: | 36319579 | Category: | Date Added: | 2022-11-02 | |
| Dept Affiliation: |
PERFORM
1 Healthy Active Living and Obesity Research Group, CHEO Research Institute, Ottawa, Ontario, Canada; Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada. Electronic address: jpchaput@cheo.on.ca. 2 School of Kinesiology and Health Studies, Queen's University, Kingston, Ontario, Canada; Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada. 3 Healthy Active Living and Obesity Research Group, CHEO Research Institute, Ottawa, Ontario, Canada. 4 Department of Psychology, Toronto Metropolitan University, Toronto, Ontario, Canada. 5 Institut Universitaire de Gériatrie de Montréal and CRIUGM, CIUSSS du Centre-Sud-de-l'Île-de-Montréal, Montreal, Quebec, Canada; PERFORM Centre, Center for Studies in Behavioral Neurobiology, Department of Health, Kinesiology and Applied Physiology, Concordia University, Montreal, Quebec, Canada. 6 Department of Psychology, Queen's University, Kingston, Ontario, Canada. 7 The University of Ottawa Institute of Mental Health Research at The Royal, Ottawa, Ontario, Canada; School of Psychology, University of Ottawa, Ottawa, Ontario, Canada. 8 School of Psychology, Laval University, Quebec City, Quebec, Canada. |
||||
Description: |
Objective: To estimate health care and productivity costs associated with insomnia symptoms in Canadian adults. Methods: Three pieces of information were needed to calculate estimates based on a prevalence-based approach: (1) the pooled relative risk estimates of health outcomes consistently associated with insomnia symptoms obtained from recent meta-analyses of prospective cohort studies; (2) the direct (health care) and indirect (lost productivity due to premature mortality) costs of these health outcomes using the Economic Burden of Illness in Canada information; and (3) the prevalence of insomnia symptoms in Canadian men (18.1%) and women (29.5%) obtained from a nationally-representative survey. Results: The direct, indirect, and total costs of insomnia symptoms in Canada in 2021 were $1.9 billion, $12.6 million, and $1.9 billion, respectively. This value represents 1.9% of the overall burden of illness costs for 2021 in Canada. The 2 most expensive chronic diseases attributable to insomnia symptoms were type 2 diabetes ($754 million) and depression ($706 million). The main contributor to the costs for type 2 diabetes and depression was prescription drugs. A 5% decrease in insomnia symptoms (from 23.8% to 18.8%) would result in an estimated $353 million in avoided costs while a 5% increase in insomnia symptoms (from 23.8% to 28.8%) would result in an estimated $333 million in additional expenditures yearly. Conclusions: Insomnia symptoms greatly contribute to the economic burden of illness in Canada. Reducing the prevalence of insomnia symptoms would reduce its societal burden. |
